Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin.

Trial Profile

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Glimepiride (Primary) ; Liraglutide (Primary) ; Metformin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Aug 2016 Status changed from recruiting to completed.
    • 20 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top